TABLE 4.

Summary of some organic nanoparticles used for liver fibrosis/cirrhosis treatment.

Nano‐platform	Proprietary name	Active ingredients	Surface modification	Cell types	Target	Reference
LNPs	mLNP‐siHMGB1	HMGB1 siRNA	Mannose	Macrophages	Mannose receptors	154
LNPs	Cur‐mNLCs	Curcumin	PS	Macrophages	Endocytosis	162
LNPs	M6P‐HSA‐MT‐SLN	Matrine	Mannose 6‐phosphate	HSCs	Mannose receptors	163
LNPs	VA‐PFD@ZIF‐8@DMPC NPs	Pirfenidone	Vitamin A	HSCs	RBPR receptors	164
LNPs	AA‐T3A‐C12/siHSP47 LNPs	HSP47 siRNA	Anisamide ligands	HSCs	Sigma receptors	155
LNPs	VA‐SLNs	Butein	VA‐Myrj52	HSCs	RBPR receptors	165
LNPs	CT‐VLNPs	siCol1α1/siTIMP‐1	Chol‐PEG‐VA	HSCs	RBPR receptors	157
Polymer NPs	HA‐PEI/siRNA	COX‐1 siRNA	HA‐PEI	LSECs	Endocytosis	166
Polymer NPs	HA@PRB/COL NPs	COL	HA	HSCs	CD44 receptor	167
Polymer NPs	T‐C‐siRNA	PDGFR‐β siRNA	Vitamin A	HSCs	RBPR receptors	168
Micelles	PEG‐PCL	Camptothecin	Folic acid	HSCs	FRα receptors	169
Micelles	Sel@GBRNPs	Selonsertib	β‐d‐Galactose	Hepatocytes	Asialoglycoprotein receptor	170

Abbreviations: Cur, curcumin; FRα, folate receptor alpha; HA, hyaluronate; HMGB1, high mobility group box 1; HSCs, hepatic stellate cells; HSP47, heat shock protein 47; LNPs, lipid nanoparticles; LSECs, liver sinusoidal endothelial cells; PDGFR‐β, platelet‐derived growth factor receptor beta; PS, phosphatidylserine; RBPR, retinol‐binding protein receptor; siRNA, small interfering RNA.